IPSEN |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 123.6 EUR | -1.75% |
|
+0.57% | +14.46% |
| 06-12 | Ipsen: share price soars, UBS confirms its recommendation | CF |
| 06-12 | IPSEN : UBS remains Buy after FDA approval | CF |
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-07-23
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
125.8
EUR
Average target price
127.3
EUR
Spread / Average Target
+1.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.46% | 11.27B | |
| +50.32% | 781B | |
| -7.71% | 350B | |
| +18.73% | 330B | |
| +7.08% | 293B | |
| +16.47% | 248B | |
| +0.12% | 221B | |
| +10.96% | 217B | |
| +2.90% | 162B | |
| -5.30% | 157B |
- Stock Market
- Equities
- IPN Stock
- News Ipsen
- France's Ipsen Names Chief Medical Officer
